JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB139447

MMP2 Inhibitor Screening Assay Kit (Fluorometric)

Be the first to review this product! Submit a review

|

(5 Publications)

MMP2 Inhibitor Screening Assay Kit (Fluorometric) (ab139447) is a complete assay system designed to screen inhibitors of matrix metalloproteinase 2 (MMP2, gelatinase A) using a quenched fluorogenic peptide: MMP Fluorogenic Substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH.

View Alternative Names

CLG4A, MMP2, 72 kDa type IV collagenase, 72 kDa gelatinase, Gelatinase A, Matrix metalloproteinase-2, TBE-1, MMP-2

1 Images
Functional Studies - MMP2 Inhibitor Screening Assay Kit (Fluorometric) (AB139447)
  • FuncS

Supplier Data

Functional Studies - MMP2 Inhibitor Screening Assay Kit (Fluorometric) (AB139447)

Inhibition of MMP2 by NNGH

Key facts

Detection method

Fluorescent

Sample types

Inhibitor compounds

Assay type

Enzyme activity

Assay Platform

Microplate reader

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Enzyme activity assay": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

MMP2 Inhibitor Screening Assay Kit (Fluorometric) (ab139447) is a complete assay system designed to screen inhibitors of matrix metalloproteinase 2 (MMP2, gelatinase A) using a quenched fluorogenic peptide: MMP Fluorogenic Substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH. Mca fluorescence is quenched by the Dpa group until cleavage by MMPs at the Gly-Leu bond separates the two moieties. The assays are performed in a convenient 96-well microplate format.

This kit is useful to screen inhibitors of MMP2, a potential therapeutic target. The MMP inhibitor NNGH is also included as a prototypic control inhibitor.

What's included?

{ "values": { "1x96Tests": { "sellingSize": "1 x 96 Tests", "publicAssetCode":"ab139447-1x96Tests", "assetComponentDetails": [ { "size":"1 x 200 µL", "name":"MMP Fluorogenic Substrate", "number":"AB139447-CMP03", "productcode":"" }, { "size":"1 x 1 Unit", "name":"96-well White Microplate 1/2 Volume", "number":"AB139447-CMP06", "productcode":"" }, { "size":"1 x 45.7 µL", "name":"MMP2 Enzyme (Human, Recombinant)", "number":"AB139447-CMP01", "productcode":"" }, { "size":"1 x 50 µL", "name":"MMP Calibration Standard", "number":"AB139447-CMP02", "productcode":"" }, { "size":"1 x 20 mL", "name":"Fluorometric Assay Buffer", "number":"AB139447-CMP05", "productcode":"" }, { "size":"1 x 50 µL", "name":"MMP Inhibitor", "number":"AB139447-CMP04", "productcode":"" } ] } } }

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
Multi
Storage information
Please refer to protocols

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The MMP-2 protein also known as matrix metalloproteinase-2 or gelatinase A is an enzyme involved in the breakdown of extracellular matrix components. It plays a critical role in tissue remodeling and cell migration. Comprised of a molecular weight of approximately 72 kDa this metalloproteinase is secreted as an inactive proenzyme that requires activation. MMP2 is expressed in various tissues including the brain heart and blood vessels where it contributes to normal physiological processes and pathological conditions.
Biological function summary

Matrix metalloproteinase-2 is mainly involved in the degradation of type IV and V collagens gelatin and fibronectin. As part of the metalloproteinase family it works alongside other MMPs to maintain tissue homeostasis and repair. MMP-2 forms part of a complex network that ensures the timely degradation of matrix components balancing synthesis and breakdown. It remains regulated by tissue inhibitors of metalloproteinases (TIMPs) preventing excessive degradation that could lead to tissue damage.

Pathways

MMP-2 plays a significant role within the extracellular matrix (ECM) remodeling and angiogenesis pathways. It interacts with various proteins including integrins and TIMP-2 to modulate cellular behaviors such as migration and invasion. MMP-2 contributes to processes like wound healing and embryonic development through its involvement in ECM degradation and new tissue formation.

Matrix metalloproteinase-2 is linked to cancer progression and cardiovascular diseases. In cancer abnormal MMP-2 activity facilitates tumor invasion and metastasis by breaking down matrix barriers. Increased MMP-2 expression associates with poor prognosis in cancers like breast and prostate. In cardiovascular diseases such as atherosclerosis it contributes to plaque destabilization and vascular remodeling. The imbalance in MMP-2 activity and its regulation by proteins like TIMP-1 are involved in the pathology of these disorders.

Product protocols

Target data

Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14.. PEX, the C-terminal non-catalytic fragment of MMP2, possesses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels.. Isoform 2. Mediates the proteolysis of CHUK/IKKA and initiates a primary innate immune response by inducing mitochondrial-nuclear stress signaling with activation of the pro-inflammatory NF-kappaB, NFAT and IRF transcriptional pathways.
See full target information MMP2

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

International journal of molecular sciences 24: PubMed37108137

2023

Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry.

Applications

Unspecified application

Species

Unspecified reactive species

Sebastian Flieger,Mao Takagaki,Natsuko Kondo,Marlon R Lutz,Yash Gupta,Hiroki Ueda,Yoshinori Sakurai,Graham Moran,Prakasha Kempaiah,Narayan Hosmane,Minoru Suzuki,Daniel P Becker

Journal of enzyme inhibition and medicinal chemistry 38:2166040 PubMed36695002

2023

Dual-target ligand discovery for Alzheimer's disease: triphenylphosphoranylidene derivatives as inhibitors of acetylcholinesterase and β-amyloid aggregation.

Applications

Unspecified application

Species

Unspecified reactive species

Marwa El-Hussieny,Mansoura A Abd-El-Maksoud,Fouad M Soliman,Marwa A Fouad,Mohamed K El-Ashrey

The Journal of clinical investigation 132: PubMed35133978

2022

Developmental endothelial locus-1 protects from hypertension-induced cardiovascular remodeling via immunomodulation.

Applications

Unspecified application

Species

Unspecified reactive species

Theresa Failer,Michael Amponsah-Offeh,Aleš Neuwirth,Ioannis Kourtzelis,Pallavi Subramanian,Peter Mirtschink,Mirko Peitzsch,Klaus Matschke,Sems M Tugtekin,Tetsuhiro Kajikawa,Xiaofei Li,Anne Steglich,Florian Gembardt,Annika C Wegner,Christian Hugo,George Hajishengallis,Triantafyllos Chavakis,Andreas Deussen,Vladimir Todorov,Irakli Kopaliani

Future medicinal chemistry 11:3161-3178 PubMed31838895

2019

Multifunctional hybrid sulfonamides as novel therapeutic agents for Alzheimer's disease.

Applications

Unspecified application

Species

Unspecified reactive species

Rayala Swetha,Devendra Kumar,Sukesh K Gupta,Ankit Ganeshpurkar,Ravi Singh,Gopichand Gutti,Dileep Kumar,Srabanti Jana,Sairam Krishnamurthy,Sushil K Singh

European journal of medicinal chemistry 150:87-101 PubMed29524731

2018

Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.

Applications

Unspecified application

Species

Unspecified reactive species

Devendra Kumar,Sukesh K Gupta,Ankit Ganeshpurkar,Gopichand Gutti,Sairam Krishnamurthy,Gyan Modi,Sushil K Singh
View all publications
websiteProtocolBooklet
en

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com